WashU Olin Accreditation and Rankings
Olin Business School at Washington University in St. Louis is accredited by the three most recognized business school accreditation organizations. As of August 2020, just over 100 of the nearly 13,000 business schools in the world earned this honor—that’s fewer than 1% of all business schools.
Accreditation from the world's leading accrediting association for business schools certifies that Olin’s programs meet or exceed a wide range of rigorous quality standards for curriculum, research, admissions standards, graduation requirements and resources.
AMBA accredits post-graduate business programs at more than 260 Business Schools in more than 75 countries, with a philosophy focused on accreditation impact, employability and learning outcomes. This accreditation certifies that Olin’s MBA programs reflect changing trends and innovation in the postgraduate education sector.
EQUIS accreditation ensures a rigorous quality control, benchmarking a school against international standards in terms of governance, programs, students, faculty, research, internationalization, ethics, responsibility and sustainability, as well as engagement with the world of practice.
#4 undergraduate business program, Poets & Quants, 2022
#14 undergraduate business program, US News & World Report, 2022
#9 undergraduate program for entrepreneurs, Princeton Review, 2021
#29 global MBA program, Financial Times, 2022
#1 MBA for entrepreneurs, Poets & Quants, 2020, 2021, 2022
#15 Graduate Entrepreneurship Studies, Princeton Review, 2021
MBA program of the year, Poets & Quants, 2019
#4 MBA program for women, Financial Times, 2018
#19 best PMBA program, US News and World Report, 2023
#18 US EMBA program, #11 in US, The Economist, 2020
#23 global EMBA (Shanghai), Financial Times, 2021
#3 global Master of Accounting program, TFE Times, 2021
#2 global Master of Finance program, TFE Times, 2021
#3 Graduate Supply chain program, Gartner, 2020
#14 open enrollment executive education program, Financial Times, 2020
#12 academic research, Financial Times, 2022